An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab.
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 03 Aug 2017 New trial record